Fulgent Genetics, a pioneering leader in genomic testing since its inception in 2011, has successfully raised $99 million in a recent funding round to further its mission of developing flexible and affordable diagnostics and therapeutics that enhance the everyday lives of patients. Renowned for its innovative technology platform, Fulgent specializes in a comprehensive range of genomic testing services that encompass oncology, anatomic pathology, infectious and rare diseases, and reproductive health. This significant investment will fuel Fulgent's expansion and enhance its capabilities in delivering high-quality, accessible care. The company is poised to utilize these funds to advance its cutting-edge offerings, including Fulgent Oncology, Fulgent BioPharma, and specialized products like HelioLiver, all designed to redefine patient management for clinicians and patients alike. With a commitment to excellence, Fulgent operates as a CLIA-certified and CAP-accredited laboratory, ensuring that patients receive the highest standards of care. By investing in innovative genomic solutions, Fulgent Genetics is not just transforming the diagnostics landscape; it is shaping the future of healthcare by empowering patients and healthcare providers with actionable insights. With this new capital, Fulgent is determined to enhance its testing menu further, innovate its service offerings, and ultimately improve patient outcomes on a broader scale. As the company continues on its journey towards redefining medicine, it stands at the forefront of a genomic revolution, dedicated to making healthcare more effective and personalized for everyone.
Fulgent Genetics Secures $99M in Funding to Revolutionize Diagnostics and Therapeutics
Recently funded 路 $99.0MHealthcare
Get the full Fulgent Genetics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
